

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

DR. REDDY'S LABORATORIES, LTD. AND DR. REDDY'S  
LABORATORIES, INC.,  
Petitioners,

v.

MONOSOL RX, LTD.,  
Patent Owner.

---

Case No. IPR2016-XXXXX

---

**DECLARATION OF METIN ÇELİK, Ph.D. IN SUPPORT OF PETITION FOR  
*INTER PARTES* REVIEW OF U.S. PATENT NO. 8,603,514**

**“UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM  
INCORPORATING TASTE-MASKING COMPOSITIONS”**

## TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION.....	1
II. QUALIFICATIONS.....	1
A. Education and Work Experience.....	3
B. Professional Affiliations, Activities, and Awards.....	4
C. Publications and Educational Involvement.....	5
D. Prior Testimonies .....	6
III. SCOPE OF THE WORK AND COMPENSATION .....	6
A. Bases for Opinion and Materials Considered.....	7
IV. SUMMARY OF OPINIONS .....	7
V. LEGAL STANDARDS.....	13
VI. PERSON OF ORDINARY SKILL IN THE ART .....	15
VII. THE ‘514 PATENT.....	15
A. Priority Date of the ‘514 Patent.....	15
B. The Challenged Claims of the ‘514 Patent .....	16
VIII. BACKGROUND AND TUTORIAL.....	21
A. Polymers.....	21
B. Particles .....	24

## TABLE OF CONTENTS

(Continued)

C.	Role of Viscosity .....	25
D.	Drying of Suspensions .....	29
E.	Role of Uniformity in Drug Formulations .....	31
F.	Flavoring of Pharmaceutical Formulations .....	33
IX.	SCOPE AND CONTENT OF THE PRIOR ART REFERENCES .....	33
A.	WO 200/42992 (Chen) (Ex. 1005).....	33
B.	U.S. Patent No. 7,067,116 (Bess) (Ex. 1004) .....	40
C.	CA 2274910 (Cremer) (Ex. 1006) .....	41
X.	INVALIDITY OF THE ‘514 PATENT .....	42
A.	Claims 1 and 62 of the ‘514 Patent are Obvious over Bess in view of Chen .....	42
B.	A POSA would combine the Teaching of Bess and Chen along with the Knowledge in the Art.....	46
C.	Additional Limitations in Independent Claims 1 and 62 do not render those claims Nonobvious over Bess and Chen.....	47
D.	The Dependent Claim Limitations Do Not Render the ‘514x Asserted Claims Nonobvious over Bess and Chen.....	47
E.	Claims 1 and 62 of the ‘514 Patent are Obvious over Chen and Cremer .....	49
F.	A POSA would combine the Teachings of Chen and Cremer along with the Knowledge in the Art.....	54

∴

## TABLE OF CONTENTS

(Continued)

G.	Additional Limitations in Independent Claims 1 and 62 do not render those claims Nonobvious over Chen and Cremer.....	55
H.	The Dependent Claim Limitations do not render the those Claims Nonobvious over Chen and Cremer.....	55
XI.	CONCLUSION .....	57

I, Metin Çelik, Ph.D. declare as follows:

**I. INTRODUCTION**

1. My name is Metin Çelik. I have been retained by counsel for Petitioner Dr. Reddy's Laboratories, Inc. of 107 College Road East, Princeton, NJ 08540 and Dr. Reddy's Laboratories, Ltd. of 8-2-337, Road No. 3, Banjara Hills, Hyderabad, India 500034) (collectively, "Dr. Reddy's") to provide opinions relating to U.S. Patent 8,603,514 ("the '514 Patent"). I further understand that Dr. Reddy's requests that the United States Patent and Trademark Office ("USPTO") cancel certain claims of the '514 patent as unpatentable. I submit this expert declaration, which addresses and supports the petition of Dr. Reddy's.

**II. QUALIFICATIONS**

2. I am currently the President of Pharmaceutical Technologies International, Inc. ("PTI"), a company that I founded in 1997. PTI develops management tools, databases and expert systems for the pharmaceutical industry worldwide and provides expert consultant services to various international pharmaceutical, food, excipient and equipment companies and to law firms throughout North America.

3. Since 2008, I am also a Research Professor of Pharmaceutical Technology at the College of Pharmacy, Near East University in Cyprus where I have established a tableting research center.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.